Last Updated: September, 2026
Trusted by 200+ Clients
This report gives the detailed analysis needed to set up an orelabrutinib production plant. It works through the main cost areas, from the cost of orelabrutinib production and the orelabrutinib plant cost to the wider orelabrutinib production plant cost. It also looks at what it takes to run the plant day to day. That covers the production process, raw materials, utilities, infrastructure, machinery & technology, manpower, packaging, transportation, and more.
Orelabrutinib is a small-molecule, covalent, highly selective inhibitor of Bruton's tyrosine kinase (BTK). It binds cysteine-481 on BTK irreversibly and shuts down B-cell receptor signaling, which is what makes it useful in B-cell malignancies, mainly relapsed or refractory CLL/SLL, MCL, and MZL. InnoCare Pharma markets it as Yinuoke in China and Hibruka in Australia, and it reaches patients as a white oral tablet. First-line CLL/SLL approval in China came recently, and multiple sclerosis trials are running outside China under a Biogen license.
The API comes from a very narrow supplier base. InnoCare holds the manufacturing rights in China and makes the drug at its own Beijing facility, while Biogen handles ex-China MS supply under an in-licensing deal; a few Chinese CDMOs and fine chemical houses provide the specialty intermediates and the piperidine-boronic-acid building block. Contract research laboratories typically purchase reference-standard materials from catalog suppliers like Selleckchem, MedKoo, and Alfa Chemistry. When assessing the demand and supply outlook, several factors need to be considered, including the patent position, the yield from InnoCare’s captive production route, the cost of the tricyclic scaffold, and reimbursement pricing under China’s National Reimbursement Drug List (NRDL). Once the material is received, laboratories generally check its quality using tests such as HPLC assay, related-substance analysis, residual-solvent testing, chiral purity, and polymorphic-form analysis.
The compound is identified by CAS 1655504-04-3 and has the molecular formula C26H25N3O3, with a molar mass of 427.5 g/mol. It is usually seen as a white or off-white crystalline solid and has little to no noticeable odor. In terms of solubility, it does not dissolve well in water, but is soluble in DMSO and methanol, along with some other polar aprotic solvents. The reported density is about 1.21 g/cm³.
The material is available in two main grades. The pharmaceutical API grade is produced to meet NMPA and TGA requirements and is supplied to InnoCare for use in tablet manufacturing. The other is the reference-standard grade, which is generally purchased by CROs and academic laboratories in smaller quantities, ranging from milligrams to grams. The finished product is supplied as 50 mg film-coated tablets under the Yinuoke and Hibruka brand names.
Oncology covers three approved indications in China: relapsed/refractory CLL/SLL, R/R MCL, and R/R MZL, all listed on the NRDL. The recent first-line CLL/SLL approval has started to lift patient numbers sharply, and Australia's TGA has approved orelabrutinib for R/R MCL. Combination trials with the BCL2 inhibitor mesutoclax and with R-CHOP for first-line MCL are progressing, and a new drug application for primary immune thrombocytopenia was accepted in China recently. Multiple sclerosis is the second family of indications: Biogen holds worldwide MS and non-China autoimmune rights and is running phase 3 studies of the CNS-penetrant tablet. Reference-standard grade takes small volumes at firmer margins, mostly for labs profiling BTK inhibition.
Most of the demand for orelabrutinib comes from oncology, accounting for roughly 90% of finished tablet volumes. Among the approved uses, R/R CLL/SLL currently represents the largest portion. Its use in first-line CLL/SLL has also been approved, which could increase its contribution over time. The remaining approved use is mainly in R/R MCL and R/R MZL. For monotherapy, the usual dose is 150 mg once a day, while ongoing combination studies involving mesutoclax and R-CHOP may lead to additional applications. For the finished tablets, buyers generally look at factors such as dissolution, dosage uniformity, assay results, and the impurity profile to ensure they meet NMPA and TGA requirements.
Autoimmune and CNS use is the second outlet and remains investigational. Biogen's license covers multiple sclerosis worldwide, and the drug's CNS-penetrant profile is the rationale for the deal. A filing for primary immune thrombocytopenia is in China, and systemic lupus, neuromyelitis optica, and other B-cell conditions are in earlier trials. This work will not consume real tablet volume until phase 3 reads out, but it drives most of the intermediate-scale clinical API demand at InnoCare.
The remaining demand comes from reference-standard applications. Suppliers such as Selleckchem, MedKoo, and Alfa Chemistry typically provide these materials in gram-scale quantities to academic laboratories and CROs. These customers generally require purity above 99%, along with checks for chiral purity and characterization using techniques such as NMR, MS, and elemental analysis. Although the volumes involved are quite small, this market tends to establish the lower end of pricing for higher-specification material.
The supply side is fairly concentrated, with InnoCare currently serving as the main commercial producer. With the composition-of-matter patents still in place, there is no generic manufacturing route available, meaning an issue at the Beijing facility could affect downstream supply across markets. The China NRDL system also puts pressure on pricing, which can affect InnoCare’s margins when reimbursement terms are renewed. Outside China, uptake in oncology has been limited so far, and international revenue is largely linked to the progress of the Biogen MS program. At the same time, orelabrutinib faces competition from established BTK inhibitors including ibrutinib, acalabrutinib, and zanubrutinib. Chinese payers may also switch between products in the class when the available clinical evidence supports doing so, while non-covalent BTK inhibitors such as pirtobrutinib provide another source of competition.
There are also some practical challenges during manufacturing. The process involves combining a chiral tricyclic scaffold with a piperidine boronic acid using Suzuki coupling, making the quality of the starting materials particularly important. Palladium residues from this step need to be reduced to within the limits set by ICH Q3D. If the polishing step does not remove enough of the metal, the batch may have to be downgraded. The acryloyl group in the final compound is sensitive to both moisture and light, so the later stages are normally handled under nitrogen and controlled humidity. Maintaining the R-configuration at the piperidine center is another important part of the process. In practice, batch rejections have been more commonly associated with palladium carryover and related-substance results than with problems in overall yield.
The value chain covers the main stages involved in producing the compound. It starts with intermediate synthesis, followed by Suzuki coupling and the steps used to establish the required chiral form, either through chiral resolution or asymmetric synthesis. The process then moves to acryloyl amidation, followed by purification and drying before the material is finally packaged under GMP conditions.
Production starts with the tricyclic scaffold and Boc-protected piperidine boronic acid being received and checked for quality. These two materials are then combined in a Suzuki coupling reaction using a palladium catalyst in 1,4-dioxane, producing the Boc-protected intermediate. The Boc group is removed with TFA in the next step. After that, the resulting piperidine is reacted with acryloyl chloride in the presence of a mild base to introduce the covalent warhead. The crude API is then extracted and washed before moving to the first crystallization step, which uses a mixed-solvent system.
The crude material is first treated with a palladium-scavenger resin to reduce residual palladium to within the limits specified by ICH Q3D. It then goes through a second crystallization step to obtain the required polymorphic form. Once dried, the API is milled to the particle size needed for tablet production, tested to confirm it meets NMPA and TGA specifications, and packaged under a nitrogen atmosphere. Manufacturing costs are largely influenced by the quality of the boronic acid, the amount of palladium catalyst used, chiral-process yield, and recovery during crystallization.
The tricyclic scaffold dominates the raw material line, a custom intermediate with no bulk market whose price reflects the multi-step synthesis behind it. The piperidine-boronic-acid building block is the next major cost, shipped from a narrow set of specialty suppliers. Palladium catalyst is a real unit cost, and it has to be reclaimed through metal-refining partners for the plant economics to work. Acryloyl chloride is cheap per kilogram but hazardous to handle, and solvent recovery on 1,4-dioxane matters because the solvent-to-product ratio at coupling is high. GMP documentation, testing, and regulatory filings are carried as fixed overhead that is heavy relative to API tonnage, and on the testing side, chiral HPLC, ICP-MS for palladium, and related-substance HPLC make up most of the spend.
The cost of the API is also affected by changes in the price and availability of palladium and acryloyl chloride. If specialty boronic acids become harder to source, the cost of the tricyclic synthesis step can increase as well. Production for MS clinical trials brings additional expenses because of the extra testing, chain-of-custody records, and smaller batch sizes involved. Since oncology APIs are often produced in relatively small batches, the amount of time a reactor is occupied can have a noticeable effect on the final cost.
GMP facilities also involve significant fixed expenses. Cleanrooms, gloveboxes, and palladium-polishing equipment need to be maintained even when they are not running at full capacity, so keeping these facilities well utilized is important for controlling the cost per batch. Qualification for the Biogen MS program also involved several months of on-site audits and related work.
The tricyclic scaffold is the primary feedstock, a custom intermediate produced by Chinese specialty fine chemical suppliers under long-term contracts with InnoCare, and its price reflects the underlying multi-step chemistry and the low volume base. The piperidine-boronic acid comes from a narrow set of specialty suppliers in China, India, and Europe, and its specifications cover assay, water content, palladium residue, and related isomers, since any residual isomer carries through to the API. Palladium catalyst ships from precious-metal producers such as Johnson Matthey and BASF, usually as a supported catalyst on carbon, and TFA, acryloyl chloride, 1,4-dioxane, and base come from bulk fine chemical suppliers.
Choosing the lowest-priced scaffold does not necessarily result in the lowest overall API cost. If the scaffold contains a high level of related substances, more purification may be needed after the Suzuki coupling, which can also increase the amount of material that falls outside specification. The quality of the boronic acid has a similar effect. Higher levels of unwanted isomers can reduce the coupling yield and create additional processing work. Palladium recovery is another cost consideration because of the value of the metal and the amount used in the process.
In practical terms, the main variable-cost drivers are the assay of the scaffold, isomer purity of the boronic acid, the amount of Pd-scavenger resin required, and the quality and recovery of the crystallization solvents.
Procurement needs to account for these quality and process requirements. Supplier contracts usually define acceptable limits for scaffold purity, boronic-acid isomers, water content, and residual metals. When a new lot arrives, it is kept in quarantine until the QC checks are completed and the material is approved for use.
For a GMP API facility, supplier qualification can involve on-site audits, a review of the impurity profile, and checks on consistency between different lots. Longer-term agreements with scaffold suppliers can also make pricing and supply schedules easier to manage. Location is another consideration. A facility based within established fine-chemical or CDMO clusters in areas such as Beijing, Shanghai, or Zhejiang can benefit from easier logistics, supplier access, communication, and regulatory coordination compared with a standalone site.
The main environmental and workplace issues are associated with the use of 1,4-dioxane, handling acryloyl chloride, and disposal of spent palladium catalyst. These materials are typically managed through closed systems, activated-carbon scrubbers for process vents, and recovery systems for dioxane. Spent palladium resin can also be sent for metal recovery rather than being treated as ordinary waste.
Wastewater from the process may contain amide solvents, halogenated compounds, and small amounts of metals, so it requires appropriate chemical and biological treatment before discharge. Energy use can be reduced by integrating heat between the crystallization stages. Improving dioxane recovery to above 90% can also have a significant effect on both waste generation and the environmental cost of the process.
The regulatory requirements depend largely on where the API is being supplied and how it is used. In China, manufacturing is subject to NMPA cGMP requirements, with the manufacturer maintaining a Drug Master File. In Australia, the finished product has been approved by the TGA under GMP requirements, including the relevant ICH Q3A, Q3C, and Q3D limits.
The Biogen MS program would bring additional requirements for supply outside China. These include the US FDA IND process and, eventually, an NDA, along with an MAA submission in Europe through the EMA. Facilities supplying these markets would also need to meet applicable requirements under 21 CFR 211 and EU GMP Annex 1. Depending on the site, environmental and occupational management may also be covered through ISO 14001 and ISO 45001 certification. At present, there is no USP or EP monograph for the molecule, as it remains under patent.
The facility would require a multi-stage production setup, including palladium removal and a controlled finishing area. Raw materials such as the scaffold and boronic acid would first be stored before moving into a glass-lined reactor for the Suzuki coupling. The coupling stage would operate under an inert atmosphere, followed by Boc deprotection and acryloyl amidation under nitrogen.
The downstream section would include filtration and centrifugation, followed by two crystallization stages and a palladium-scavenger column. Chiral chromatography could be added when needed. After drying and processing, the API would pass through a nitrogen-purged mill before being packed in an area with controlled humidity.
The facility would also need supporting utilities such as clean steam, purified water, WFI-grade water, chilled brine, nitrogen, and HEPA-filtered air for the cleanrooms. Solvent vapors would be handled through a thermal oxidizer. Quality-control laboratories would typically be equipped with chiral HPLC, ICP-MS, GC for residual solvents, moisture titration equipment, and HPLC systems for related-substance testing.
From a building and site perspective, the setup would include cGMP process bays, gowning areas, a controlled-access warehouse for the API, bunded solvent storage, and dedicated QC laboratory space.
The main operating expenses come from the materials used in the process and the controls needed to meet GMP requirements. Key raw-material costs include the scaffold, boronic acid, palladium catalyst, TFA, acryloyl chloride, dioxane, and the base. Other ongoing expenses include WFI water, labor, testing, GMP documentation, equipment maintenance, wastewater treatment, packaging, and freight.
The cost of producing a saleable kilogram also depends on how long each batch takes, the yield from the coupling step, and how efficiently palladium can be recovered. Costs can vary between facilities depending on their production capacity, whether they use chiral synthesis or chiral resolution, the design of the palladium-polishing system, cleanroom requirements, and the markets they are qualified to supply.
In day-to-day operations, factors such as scaffold pricing, coupling yield, palladium and dioxane recovery, GMP-related overhead, and testing requirements have the biggest influence on the final running cost.
A suitable manufacturing location would ideally be close to a dependable supplier of the tricyclic scaffold and part of an established fine-chemical or CDMO cluster. Having access to workers with cGMP experience is another important requirement. For the current InnoCare setup, areas such as Beijing, Shanghai, Zhejiang, and Jiangsu provide this type of manufacturing environment. If a generic manufacturing route becomes viable in the future, established pharmaceutical hubs such as Hyderabad and Ahmedabad in India could also be considered.
The site would need appropriate wastewater-treatment facilities capable of handling streams containing halogenated compounds and metals. Reliable road, air, and port connections would also be useful, particularly for temperature-controlled shipments to formulation facilities and Biogen's fill-finish partners.
One of the main decisions for the facility is whether to manufacture only the API or also produce the scaffold internally. An API-only setup would require less initial investment, although it would leave the business more dependent on changes in scaffold pricing and availability. Adding upstream scaffold production would increase the initial capital requirement but could provide greater control over supply.
There is also a choice to make around the piperidine stereochemistry. Using chiral synthesis or resolution can affect both the required equipment and the overall yield of the process. Production capacity would need to be sized around current oncology requirements, with additional room if demand increases during the MS Phase 3 program. Supply qualification for Biogen's MS program may also take a year or longer, adding to the planning timeline.
Overall, the business case depends largely on maintaining captive API supply for InnoCare and meeting the supply requirements associated with the Biogen licensing arrangement.
China is the sole commercial production region for orelabrutinib. InnoCare runs API and formulation manufacturing in Beijing, with clinical-supply lots handled through partner CDMOs, and the molecule is not made outside China at commercial scale. If the MS phase-3 program reads out, Biogen will need to qualify one or more ex-China API suppliers. Reference-standard material is finished by catalog suppliers in the US, Europe, India, and China from small quantities sourced through licensed channels or independent CRO synthesis; bulk API is made at InnoCare's Beijing facility, while research-grade lots run on smaller lines at the catalog houses. Australia is the first ex-China tablet market under the TGA approval.
InnoCare Pharma Limited
Biogen Inc.
Selleckchem
MedKoo Biosciences
Alfa Chemistry
BOC Sciences
Orelabrutinib Production Cost Report
Choose What's Right for You
Pay Via
| Particulars | Details |
|---|---|
| Product Name | Orelabrutinib |
| Scope | Production Process: Process Flow, Material Flow, Material Balance Raw Material and Product Specifications: Raw Material Consumption, Product and Co-product Generation Land and Site Cost: Offsites/Civil Works, Equipment Cost, Auxiliary Equipment Costs, Contingency, Engineering and Consulting Charges, Working Capital Variable Cost: Raw Material, Utilities, Other Variable Costs Fixed Cost: Labor Requirements and Wages, Overhead Expenses, Maintenance Charges, Other Fixed Costs Financing Costs: Interest on Working Capital, Interest on Loans Other Costs: Depreciation Charges, General Sales and Admin Cost |
| Currency | US$ (Data can also be provided in the local currency) |
| Customization Scope | The report can be customized as per the requirement of the customer |
| Post-Sale Analysts Report | 10-12 weeks of post-purchase analyst support after report delivery for any queries from the deliverable |
| Delivery Format | PDF and Excel format through email (editable version in PPT/Word format of the report can be also provided on special request) |
At Procurement Resource, we focus on improving the should-cost of production for orelabrutinib and map every stage of the route, from tricyclic-scaffold receipt through Suzuki coupling, Boc removal, acryloyl amidation, palladium polish, chiral and polymorph crystallization, milling, and GMP packaging. The cost model resolves each input separately, including the scaffold, piperidine-boronic acid, palladium catalyst, TFA, acryloyl chloride, dioxane, WFI water, GMP labor, analytical testing, wastewater treatment, packaging, and freight. We evaluate CAPEX and OPEX as cost per kilogram of saleable API, isolating the scaffold share, the palladium share, and the GMP overhead share, since these three items set most of the delivered cost for a small-batch oncology API.
Alongside the cost build-up, the report identifies Suzuki coupling and chiral chromatography technology providers and offers a supplier database for the scaffold, boronic acid, catalyst, solvents, and analytical services. It sets out a feasible plant layout covering coupling and amidation bays, the Pd polish, crystallization trains, the mill room, packaging, and QC laboratories. By modeling coupling yield, palladium recovery, dioxane recovery, and GMP overhead against batch size, the analysis helps reduce the cash production cost and keep you competitive in the orelabrutinib market. It supports decisions on scaffold sourcing, chiral synthesis versus resolution, plant scale, site location in a Chinese or Indian fine chemical cluster, and customer qualification for InnoCare, Biogen, and the MS supply chain.
Lead - Social & Development Research
Delivering procurement intelligence and supply chain analytics across healthcare, FMCG, and chemicals sectors, with expertise in cost modeling, vendor mapping, and spend optimization to support data-driven sourcing decisions and procurement outcomes.
Need more help?
Still Need Help?
Compare & Choose the Right Report Version for You
How to Order Your Report?
